



Narhex Life Sciences Ltd

Level 24, 44 St George's Terrace
PERTH WA 6000
P: +61-8-6211 5099
F: +61-8-9218 8875

ABN: 51 094 468 318

29 April 2015

Company Announcements Office
Australian Securities Exchange
10th Floor
20 Bond Street
SYDNEY NSW 2000

Dear Sir

ASX WAIVER FROM LISTING RULE 10.13.3

Narhex Life Sciences Limited ("**Company**") advises that ASX Limited ("**ASX**") has granted the Company a waiver from ASX listing rule 10.13.3 on the terms set out below.

DECISION:

1. Based solely on the information provided, ASX grants the Company a waiver from listing rule 10.13.3 in connection with the issue of up to 25,000,000 ordinary fully paid shares to Trident Capital Pty Ltd ("**Trident**") and up to 5,625,000 ordinary fully paid shares to SOBOL Capital Pty Ltd ("**SOBOL**") ("**Facilitation Shares**") on a pre-consolidated basis to the extent necessary to permit the notice of meeting seeking shareholder approval for the issue of the Facilitation Shares for the purposes of listing rule 10.11 ("**Notice**") to state the Facilitation Shares will be issued more than 1 month after the date of the shareholders' meeting ("**Meeting**") on the following conditions.
 - 1.1 The Facilitation Shares are issued no later than 27 August 2015.
 - 1.2 The Facilitation Shares be issued at the same time as other securities to be issued under the prospectus.
 - 1.3 The Company releases the terms of the waiver to the market immediately.
 - 1.4 Shareholders approve the issue of the Facilitator Shares at the Meeting.
2. ASX has considered listing rule 10.13.3 only and makes no statement as to the Company's compliance with other listing rules.

Yours faithfully

Nicki Farley
Company Secretary